BFLY · Butterfly Network, Inc.

Current Thesis

The narrative leg an investor buys here is "Ultrasound-on-Chip goes mainstream" Butterfly's semiconductor handheld ultrasound (a single silicon chip replacing piezoelectric crystals) reframed from a hardware-device story into an AI-software plus chip-licensing platform. Q1 2026 (reported April 30) put numbers behind it: revenue $26.5M, +25% YoY, gross margin 69%, with Butterfly Embedded (the chip-licensing arm) up 147% YoY and the first FDA-cleared "blind sweep" AI guidance tool clearing. Management reaffirmed FY2026 revenue of $117–121M (~20–24% growth) and guided Q2 to $27–31M. The fundamental narrative is genuinely ACCELERATING. The tape is the caution: the stock ran from a $1.33 52-week low to a $5.72 high (~+107% on the year) and then stalled in the $4.60–5.10 zone through early June while the Chief Business Officer sold ~$1.9M of stock into the move. Story accelerating; the easy price gain may already be spent.

Bull Case

• Q1 2026 revenue $26.5M, +25% YoY on a 69% gross margin; FY2026 guide reaffirmed at $117–121M (~20–24% growth), reported April 30, 2026.
• Butterfly Embedded licensing the Ultrasound-on-Chip to third parties grew revenue 147% YoY in Q1, with new partnership agreements described as under negotiation on the call. This asset-light, high-margin licensing optionality is what justifies a software multiple rather than a device multiple.
• First FDA-cleared "blind sweep" AI tool (Q1 2026) lets minimally-trained users capture diagnostic images, widening the addressable market beyond sonographers into primary care, global health, and the home.
• Commercial cadence stacked through 2026: Compass AI enterprise software (closed its first enterprise deal of the year, launched Q4 2025), HomeCare first commercial agreement targeted for H1 2026 with statewide deployment slated for Q3, and Octiv (wholly-owned subsidiary holding the exclusive IP license for non-competitive applications).
• Adjusted EBITDA loss narrowed to $6.1M in Q1 from $9.1M a year earlier; the loss-narrowing trajectory supports a re-rating if ~25% growth holds.
• Sell-side coverage is small but uniformly constructive roughly 4 Buy / 0 Hold / 0 Sell, average price target near $5.80 with upside scenarios cited toward $7.50+; William Blair initiated coverage in 2026.

Bear Case

• Insiders are distributing into the strength. Founder Jonathan Rothberg filed intent to sell 352k shares (Jan 6, 2026); insiders were net sellers of ~$6.2M over the trailing 12 months. Management selling into a social-driven pop is the opposite of conviction.
• The June advance ran largely on a surge in retail social-media velocity on a ~$1.3B small-cap, with no confirming unusual options activity and no insider buying only insider sales. Reflexive spikes of this kind round-trip in days.
• Still deeply unprofitable: net loss $12.7M and adjusted EBITDA loss $6.1M in Q1; the FY guide embeds a $21–25M EBITDA loss for 2026. The breakeven path depends on continued ~25% growth that has not been de-risked.
• Valuation leaves no slack: ~$1.27B market cap on ~$117–121M of 2026 revenue is roughly 10–11x forward sales for a sub-25% grower with hardware still in the mix. That multiple needs the Embedded/AI-software mix to keep compounding to hold.
• Price stalled below the $5.72 high and faded toward $4.66 by June 8 even as the fundamentals improved a divergence that often precedes a deeper retrace once retail flow cools.

Setup & Price Structure

• 52-week range $1.33 $5.72; one-year return ~+107%; market cap ~$1.27B.
• The stock broke out to the $5.72 high, then pulled back into a $4.60–5.10 consolidation through early-to-mid June 2026 (~$4.78 on June 8). It remains above the rising 50- and 200-day EMAs, so the longer-term uptrend structure is intact despite the near-term stall.
• The defining structural level is the breakout base around $4.40–4.50 the shelf the move launched from. Holding it keeps the trend; a daily close below it says the breakout failed and opens a fill back toward the $3.50–4.00 zone.
• Flow confirmation is the missing piece: the advance ran on social velocity without corroborating call-volume or accumulation, and the only insider prints were sales.
• This is an emergent-narrative small-cap, not a liquid compounder position math should assume two-sided gap risk and a wide stop.

Catalyst Calendar (next 30 days)

• 2026-06-18 TD Cowen Medical Devices Emerging Growth Call Series, 12:00pm ET; CEO Joseph DeVivo, CFO John Doherty, SVP Innovation David Horsley. Fireside format incremental rather than binary, but the nearest dated event and a venue where Embedded and HomeCare commentary can move the tape.
• Through June 2026 (H1 target) HomeCare first commercial agreement targeted; any signed deal is a discrete catalyst, with statewide deployment slated for Q3 2026.
• Unscheduled Butterfly Embedded partnership agreements described as "under negotiation" on the Q1 call; a signed chip-licensing deal is the highest-leverage event and has no fixed date.
• ~late July / early August 2026 (est.) Q2 2026 earnings (Q1 landed April 30); guided to $27–31M revenue. Outside the 30-day window but the next binary; avoid fresh exposure into the print while the date is unconfirmed.

What Would Change Our Mind

• Bull confirmation: a signed Butterfly Embedded licensing deal or a HomeCare commercial agreement, paired with the stock reclaiming and holding above the $5.72 high on expanding volume that converts the social spike into a fundamentally-fueled breakout worth sizing up.
• Invalidation: a daily close below the ~$4.40 breakout base (loss of the rising 50-EMA structure that defined the move off $1.33), OR Q2 2026 revenue printing below the $27M guide floor / any cut to the $117–121M FY guide. Either confirms the June move was fading retail froth, not a durable narrative leg.
• Continued heavy insider selling (further Cashman or Rothberg Form 4s) while price stalls would corroborate the distribution read and argue for standing aside until a cleaner base forms.

Correlation Notes

• Trades with the small-cap medtech-diagnostics and AI-enabled point-of-care basket; high-beta, risk-on healthcare flows drive it week to week more than device-sector fundamentals.
• High social-velocity sensitivity ties it to retail-momentum rotations (the "AI in healthcare going public" trade) far more than to large-cap medtech such as ISRG or GEHC it can decouple sharply when retail flow rotates out.
• As a sub-$5 small-cap it carries broad risk-appetite beta: a VIX spike or an IWM drawdown hits it harder than the index, and liquidity thins quickly on down days, widening slippage on stops.